Compare Research Peptides
Select 2 peptides to compare benefits, dosage, administration routes, mechanisms, and side effect profiles side by side.
Loading comparison tool…
Select 2 peptides to compare benefits, dosage, administration routes, mechanisms, and side effect profiles side by side.
Thymosin Alpha-1 TA1 | VIP Vasoactive Intestinal Peptide | |
|---|---|---|
| Evidence Grade | BEvidenceGrade BSmaller human trials, observational studies, or approved in 30+ countries | BEvidenceGrade BSmaller human trials, observational studies, or approved in 30+ countries |
| Regulatory | CompoundableCompoundableLegal to compound in the US; approved in other jurisdictions or has historical approval | Research OnlyResearch OnlyNo regulatory approval in any major jurisdiction; for research use only |
| Category | Immune & Inflammatory Modulation | Immune & Inflammatory Modulation |
| Key Benefits |
|
|
| Dosage | 0.8-3.2 mg mg | 50 mcg mcg |
| Frequency | 2-3x per week | 4x daily |
| Administration | Subcutaneous | Intranasal |
| Mechanism | Thymosin Alpha-1 is a peptide naturally produced by the thymus gland that plays a central role in immune function. It modulates the immune system, enhances T-cell function, and has been used as an adjuvant therapy for various conditions including hepatitis and cancer. | VIP is a neuropeptide with wide-ranging effects including immune modulation, neuroprotection, and treatment of chronic inflammatory response syndrome (CIRS). |
| Side Effects / Risks | Not specified | Not specified |
| Research Status | Approved in some countries (not FDA approved in US) | Research compound - used clinically for CIRS |
TA1
Immune & Inflammatory ModulationDosage
0.8-3.2 mg mg, 2-3x per week
Administration
Key Benefits
Research Status
Approved in some countries (not FDA approved in US)
Vasoactive Intestinal Peptide
Immune & Inflammatory ModulationDosage
50 mcg mcg, 4x daily
Administration
Key Benefits
Research Status
Research compound - used clinically for CIRS